Spero Therapeutics
113 articles with Spero Therapeutics
-
Clinical Catch-Up: June 14-18
6/21/2021
It was another busy week of clinical trial announcements. Here’s a look. -
Spero Therapeutics Announces the Initiation of Bronchoalveolar Lavage and Renal Impairment Clinical Trials of SPR206
6/15/2021
Spero Therapeutics, Inc. today announced the initiation of two Phase 1 trials of SPR206, an intravenously (IV)-administered next-generation polymyxin product candidate.
-
Spero Therapeutics Awarded up to $23 Million by the National Institute of Allergy and Infectious Diseases to Support the Development of SPR206
5/17/2021
The National Institute of Allergy and Infectious Diseases will fund the continued clinical development of product candidate SPR206
-
Spero Therapeutics to Participate at the Berenberg Conference USA
5/13/2021
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat at the Berenberg Conference USA,
-
Spero Therapeutics Announces First Quarter 2021 Operating Results and Provides Business Update
5/6/2021
Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, announced financial results for the first quarter ended March 31, 2021 and provided a business update.
-
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 30, 2021
4/30/2021
Spero Therapeutics, Inc. announced that on April 30, 2021, the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 28,600 shares of its common stock to three new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan.
-
Spero Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on Thursday, May 6, 2021
4/29/2021
Spero Therapeutics, Inc. announced that it will host a conference call and live audio webcast on May 6, 2021 at 4:30 p.m. ET to report its first quarter 2021 financial results and provide an update on its business and pipeline.
-
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 31, 2021
3/31/2021
Spero Therapeutics, Inc. announced that on March 31, 2021 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 22,050 shares of its common stock to three new employees under the Spero Therapeutics, Inc.
-
Spero Therapeutics Announces Fourth Quarter and Full-Year 2020 Operating Results and Provides Business Update
3/11/2021
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced financial results for the fourth quarter and full-year ended December 31, 2020 and provided a business update.
-
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2020 Financial Results on Thursday, March 11, 2021
3/3/2021
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on March 11, 2021
-
Spero Therapeutics to Present at Investor Conferences in March
2/25/2021
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present at the following investor conferences in March 2021
-
It was a busy week for clinical trial updates. Here’s a look.
-
Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial
2/5/2021
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that the United States Food and Drug Administration (FDA) informed Spero that a clinical hold has been placed on its Phase 2a clinical trial of SPR720,
-
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 29, 2021
1/29/2021
Spero Therapeutics, Inc. announced that on January 29, 2021 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 74,300 shares of its common stock to six new employees under the Spero Therapeutics, Inc.
-
Spero Therapeutics Announces Issuance of Allowance for a U.S. Patent Covering Lead Candidate Tebipenem HBr
1/21/2021
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,889,587,
-
Everest Medicines Announces Amended Agreement with Spero Therapeutics
1/18/2021
Spero will assign relevant SPR206 patents to Everest Medicines in Greater China, South Korea and certain Southeast Asian countries
-
Spero Therapeutics Announces Appointment of Sath Shukla as Chief Financial Officer
12/17/2020
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the appointment of Satyavrat “Sath” Shukla, CFA, as Chief Financial Officer, effective as of January 4, 2021
-
Spero Therapeutics Added to the NASDAQ Biotechnology Index
12/16/2020
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 21, 2020. The NBI is designed t
-
Spero Therapeutics Announces First Patient Dosed with SPR720 in Phase 2a Clinical Trial in Patients with Nontuberculous Mycobacterial Pulmonary Disease
12/10/2020
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections, today announced that it has initiated dosing in patients with nontuberculous mycobacterial pulmonary disease (NTM-PD) in its dose-ranging Phase 2a clinical trial of SPR720,
-
Spero Therapeutics Announces Appointment of Tamara Joseph as Chief Legal Officer
12/2/2020
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the appointment of Tamara Joseph, J.D., L.L.M., as Chief Legal Officer, effective as of today.